Activation of peripheral and spinal histamine H3 receptors inhibits formalin-induced inflammation and nociception, respectively.
Pharmacological activation of histamine H3 receptors is known to reduce the release of inflammatory peptides, thereby reducing pain and inflammation, but the site(s) and mechanism(s) of these effects are currently unknown. The present study addressed these questions by examining the effects of the H3 agonist immepip and the H3 antagonist thioperamide on nociceptive behaviors and swelling produced during the rat formalin test. Systemic administration of immepip (5 and 30 mg/kg, s.c.) significantly attenuated formalin-induced flinching but not licking responses during both phases. This attenuation was reversed by either systemic (15 mg/kg, i.p.) or intrathecal (20 or 50 microg) administration of thioperamide. Furthermore, immepip (30 mg/kg, s.c.) significantly inhibited formalin-induced swelling, an action which was completely reversed by systemic (15 mg/kg, i.p.), but not intrathecal (50 microg) thioperamide. Also consistent with this pattern, intrathecal immepip (50 microg) reduced flinching responses, but had no effect on formalin-induced paw swelling. The present findings suggest that activation of H3 receptors located on peripheral and spinal terminals of deep dermal fibers attenuates formalin-induced swelling and flinching, respectively. Pharmacological stimulation of H3 receptors could be an important therapeutic approach for many disorders related to deep dermal or inflammatory pain.
Cannon
Keri E
KE
Center for Neuropharmacology and Neuroscience, Albany Medical College MC-136, Albany, NY 12206, USA.
Leurs
Rob
R
Hough
Lindsay B
LB
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D001921:Brain / Q000187:drug effects; D004487:Edema / Q000139:chemically induced / Q000517:prevention & control; D005557:Formaldehyde; D017442:Histamine Agonists / Q000494:pharmacology*; D006633:Histamine Antagonists / Q000494:pharmacology*; D007093:Imidazoles / Q000494:pharmacology*; D007249:Inflammation / Q000139:chemically induced* / Q000517:prevention & control*; D007278:Injections, Spinal; D008297:Male; D009411:Nerve Endings / Q000187:drug effects; D009412:Nerve Fibers / Q000187:drug effects; D009475:Neurons, Afferent / Q000187:drug effects; D010147:Pain Measurement / Q000187:drug effects*; D017933:Peripheral Nervous System / Q000187:drug effects / Q000378:metabolism*; D010880:Piperidines / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D018100:Receptors, Histamine H3 / Q000187:drug effects*; D012867:Skin / Q000294:innervation; D013116:Spinal Cord / Q000187:drug effects / Q000378:metabolism*
D017442:Histamine Agonists; D006633:Histamine Antagonists; D007093:Imidazoles; D010880:Piperidines; D018100:Receptors, Histamine H3; C085755:4-(1H-imidazol-4-ylmethyl)piperidine; D005557:Formaldehyde; C052075:thioperamide
Eur J Pharmacol. 2000 Mar 10;391(1-2):81-9
10720638
J Med Chem. 1994 Feb 4;37(3):332-3
8308858
Neuroscience. 2001;102(4):937-44
11182255
Prog Neurobiol. 2001 Apr;63(6):637-72
11164999
Mech Dev. 2001 Jul;105(1-2):167-73
11429293
J Neurosci. 2001 Sep 15;21(18):7236-46
11549734
Neuropharmacology. 2001 Dec;41(8):928-34
11747897
Eur J Pharmacol. 1995 Jan 24;273(1-2):83-8
7537682
J Neurosci. 1995 May;15(5 Pt 1):3328-41
7751913
Br J Pharmacol. 1995 Apr;114(7):1518-22
7606356
Eur J Pharmacol. 1995 Apr 24;277(2-3):243-50
7493615
Circ Res. 1996 May;78(5):863-9
8620607
Neurosci Lett. 1996 Apr 12;208(1):45-8
8731171
Eur J Pharmacol. 1995 Dec 12;287(2):127-33
8749026
Br J Pharmacol. 1996 Dec;119(8):1656-64
8982515
Brain Res. 1997 Apr 25;755(1):9-16
9163536
J Pharmacol Exp Ther. 1997 Jun;281(3):1085-94
9190840
Neuroscience. 1997 Sep;80(1):241-9
9252235
Pharmacol Rev. 1997 Sep;49(3):253-78
9311023
J Comp Neurol. 1997 Dec 29;389(4):545-68
9421138
Neuroscience. 1998 Jan;82(1):223-40
9483516
Eur J Pharmacol. 1998 Dec 4;362(2-3):149-55
9874165
Prog Neurobiol. 1999 Jan;57(1):1-164
9987804
Z Rheumatol. 1998;57 Suppl 2:8-13
10025074
Brain Res Mol Brain Res. 1999 Mar 20;66(1-2):24-34
10095074
Brain Res Bull. 1999 Jan 15;48(2):129-41
10230704
Eur J Pharmacol. 1999 Apr 23;371(1):23-30
10355590
J Pain. 2005 Mar;6(3):193-200
15772913
Mol Interv. 2006 Apr;6(2):77-88, 59
16565470
Eur J Pharmacol. 2006 Jul 10;541(1-2):53-6
16762339
Pain. 2007 May;129(1-2):76-92
17134835
Prog Neurobiol. 2002 Apr;66(6):355-474
12034378
Neuroscience. 2002;114(1):173-93
12207964
Pain. 2003 May;103(1-2):7-9
12749953
Eur J Pharmacol. 2003 Jun 6;470(3):139-47
12798951
Physiol Behav. 1976 Dec;17(6):1031-6
14677603
Biochem Soc Trans. 1980 Feb;8(1):150-5
6102933
Nature. 1980 Jul 10;286(5769):155-7
6157098
Br J Pharmacol. 1980 Aug;69(4):615-23
6108140
J Neurosci. 1983 Feb;3(2):399-406
6185658
Neurosci Lett. 1985 Jun 12;57(2):125-30
2412189
Brain Res. 1987 Jun 23;414(1):143-8
2441798
J Physiol. 1987 Oct;391:141-67
2451003
Prog Brain Res. 1988;77:313-20
3064174
Brain Res. 1989 Jul 3;491(1):93-101
2788478
Neuroscience. 1989;31(3):807-15
2480554
J Pharmacol Exp Ther. 1990 Mar;252(3):1261-8
1690801
Neuroscience. 1991;43(1):197-209
1717884
Pain. 1992 Oct;51(1):5-17
1454405
Neuroscience. 1993 Jan;52(1):169-89
8381924
J Neurosci. 1993 Jun;13(6):2273-86
8501507
Anesthesiology. 1993 Aug;79(2):270-81
8102041
J Pharmacol Exp Ther. 2000 Oct;295(1):219-25
10991982